Takara. has filed a patent for a method and composition that allows for the isolation and analysis of nucleic acid molecules in a single tube or vessel. The method is suitable for use with low quality or small quantity samples and offers improved concordance rates and signal to noise ratio compared to existing methods. The patent suggests potential applications in clinical settings such as infectious disease diagnosis, pre-implantation genetic testing, prenatal or cancer diagnosis. GlobalData’s report on Takara gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Takara Holdings Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Takara, Anti-viral antigen-based compositions was a key innovation area identified from patents. Takara's grant share as of September 2023 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Method for preparing nucleic acid molecules from a sample

Source: United States Patent and Trademark Office (USPTO). Credit: Takara Holdings Inc

A recently filed patent (Publication Number: US20230313281A1) describes a method for preparing nucleic acid molecules from a sample. The method involves several steps, including lysing the sample to release the nucleic acid molecules, isolating the released molecules using beads for binding, and adding reagents for performing a nucleic acid assay.

In this method, the sample can be optionally lysed using a lysis reagent that may contain a protease. The released nucleic acid molecules are then isolated using a plurality of beads, which can be magnetic beads. These beads bind to the nucleic acid molecules, allowing for their separation from the rest of the sample.

Once the nucleic acid molecules are bound to the beads, one or more reagents are added for performing a nucleic acid assay. The assay can be various techniques such as polymerase chain reaction, whole genome amplification, targeted sequencing, whole transcriptome amplification, sequencing, or any combination thereof. The assay is performed to determine at least one genetic variant, which can include aneuploidy, mosaicism, single nucleotide polymorphism, or any combination thereof.

The method can be performed in a single vessel, allowing for a streamlined and efficient process. Additionally, some or all of the steps can be performed simultaneously, further enhancing the efficiency of the method.

The sample used in this method can be selected from a wide range of sources, including blood, plasma, urine, saliva, feces, cerebrospinal fluid, semen, breast milk, and various other bodily fluids. It can also include somatic cells, germ cells, fetal cells, environmental samples, and various other types of samples.

Another embodiment of the method described in the patent involves directly eluting the bead-bound nucleic acid molecules into reagents for performing the nucleic acid assay. This eliminates the need for separate elution steps, simplifying the process further.

Overall, this patent describes a method for preparing nucleic acid molecules from a sample that offers efficiency, simplicity, and versatility. The method can be applied to various samples and can be used for determining genetic variants using different nucleic acid assays.

To know more about GlobalData’s detailed insights on Takara, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies